High-Dose Vitamin D3 for Diabetic Foot Ulcer Healing: Randomized Controlled Trial
Key facts
- Who runs it
- Universitas Sriwijaya
- Where
- Indonesia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 24 people enrolled
- Started
- 1 Jul 2024
- Ended
- 31 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Vitamin D3
- Placebo
- Record updated
- 24 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Diagnosis of diabetic foot ulcer (DFU) Serum 25-hydroxyvitamin D level < 30 ng/mL Willingness and ability to provide written informed consent Ability to comply with study procedures and follow-up visits
Who cannot take part
- Currently undergoing cancer treatment Pregnant or breastfeeding Current use of vitamin D supplementation History of autoimmune disease Chronic kidney disease with estimated GFR < 30 mL/min/1.73 m² Abnormal liver function tests (AST or ALT ≥ 3× upper normal limit) Ankle-brachial index (ABI) < 0.4 Presence of osteomyelitis Proven sepsis Allergy to vitamin D3 Amputation prior to randomization Withdrawal of consent during the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of high-dose vitamin D3 supplementation in improving diabetic foot ulcer (DFU) healing. DFUs are common, serious complications of diabetes, often associated with delayed wound healing due to persistent inflammation, impaired angiogenesis, and imbalances between matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1). Vitamin D deficiency is prevalent among DFU patients and is linked to impaired fibroblast function, poor angiogenesis, and increased inflammation.
Read full original descriptionShow less
Participants with DFUs and serum vitamin D levels <30 ng/mL will be randomized to receive either 10,000 IU oral vitamin D3 daily or placebo for 28 days, in addition to standard DFU care. Primary outcomes include changes in tissue MMP-9/TIMP-1 expression ratio and wound healing progression. The study will provide evidence on whether high-dose vitamin D3 can serve as a safe, effective adjunctive therapy in DFU management.
The 2 groups in the trial
- Experimental: High-dose Vitamin D3Treatment being tested
Description: Participants receive oral vitamin D3, 10,000 IU daily for 28 days, plus standard care for diabetic foot ulcers. Intervention Name: Vitamin D3 (Cholecalciferol) Type: Dietary Supplement Dosage: 10,000 IU daily Duration: 28 days
Treatment: Vitamin D3
- Placebo Comparator: PlaceboPlacebo, for comparison
Description: Participants receive oral placebo daily for 28 days, plus standard care for diabetic foot ulcers. Intervention Name: Placebo Type: Inactive substance Dosage: Matched placebo daily Duration: 28 days
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effectiveness of High-Dose Vitamin D3 in Improving Diabetic Foot Ulcer Healing by Reducing the MMP-9 to TIMP-1 Ratio: Randomized Double-Blind Placebo-Controlled Trial
- Record updated
- 24 August 2025